SHLP2 vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | SHLP2 | Substance P |
|---|---|---|
| Mechanism | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |